Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Current Leases (2019 - 2025)

Silence Therapeutics' Current Leases history spans 7 years, with the latest figure at $89000.0 for Q4 2025.

  • For Q4 2025, Current Leases fell 23.93% year-over-year to $89000.0; the TTM value through Dec 2025 reached $89000.0, down 23.93%, while the annual FY2025 figure was $89000.0, 23.93% down from the prior year.
  • Current Leases for Q4 2025 was $89000.0 at Silence Therapeutics, up from $85000.0 in the prior quarter.
  • Across five years, Current Leases topped out at $523126.0 in Q4 2022 and bottomed at $60000.0 in Q1 2025.
  • The 5-year median for Current Leases is $117000.0 (2024), against an average of $182995.7.
  • The largest annual shift saw Current Leases tumbled 58.99% in 2021 before it surged 183.26% in 2022.
  • A 5-year view of Current Leases shows it stood at $184677.5 in 2021, then soared by 183.26% to $523126.0 in 2022, then plummeted by 57.53% to $222166.2 in 2023, then crashed by 47.34% to $117000.0 in 2024, then fell by 23.93% to $89000.0 in 2025.
  • Per Business Quant, the three most recent readings for SLN's Current Leases are $89000.0 (Q4 2025), $85000.0 (Q3 2025), and $60000.0 (Q1 2025).